Pergialiotis V, Daskalakis G, Thomakos N, et al. - In this systematic review, researchers gathered evidence with respect to the ability of prechemotherapy hemoglobin (Hgb) levels in predicting ovarian cancer survival (OC). They identified 11 articles, including 1,816 women with OC, identified from the Medline, Scopus, Clinicaltrials.gov, EMBASE, Cochrane Central Register of Controlled Trials CENTRAL, and Google Scholar databases searched till July 30, 2018. The meta-analysis included 5 articles with 856 OC patients. Increased odds of overall survival were reported in patients with Hgb levels > 12 g/dL vs those with anemia. Overall, the worse overall survival of OC patients can potentially be predicted by prechemotherapy Hgb levels below the threshold of 12 g/dL, as indicated by the current evidence.